Xuejun Chen

List of Publications by Year
in descending order

32 papers	3,736 citations	236925 25 h-index	414414 32 g-index
33 all docs	33 docs citations	33 times ranked	4323 citing authors

#	Article	IF	Citations
1	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports, 2022, 38, 110199.	6.4	19
2	Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice. STAR Protocols, 2022, 3, 101180.	1.2	0
3	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine, 2022, 28, 1022-1030.	30.7	34
4	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. Immunity, 2021, 54, 324-339.e8.	14.3	36
5	Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. JCI Insight, 2021, 6, .	5.0	25
6	Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques. PLoS Pathogens, 2021, 17, e1009738.	4.7	7
7	A multiclade envâ€“gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021, 27, 2234-2245.	30.7	80
8	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nature Communications, 2020, 11, 70.	12.8	37
9	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18754-18763.	7.1	53
10	Immune checkpoint modulation enhances HIV-1 antibody induction. Nature Communications, 2020, 11, 948.	12.8	27
11	Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. Immunity, 2019, 51, 398-410.e5.	14.3	107
12	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. Cell, 2019, 178, 567-584.e19.	28.9	106
13	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	4.7	56
14	Improvement of antibody functionality by structure-guided paratope engraftment. Nature Communications, 2019, 10, 721.	12.8	27
15	Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. Journal of Clinical Investigation, 2019, 129, 4832-4837.	8.2	11
16	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. Cell Reports, 2018, 22, 1798-1809.	6.4	52
17	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. Immunity, 2018, 49, 301-311.e5.	14.3	110
18	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine, 2018, 24, 857-867.	30.7	256

#	Article	IF	Citations
19	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	3.4	40
20	Preferential induction of cross-group influenza A hemagglutinin stemâ€“specific memory B cells after H7N9 immunization in humans. Science Immunology, 2017, 2, .	11.9	84
21	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science, 2017, 358, 85-90.	12.6	225
22	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	12.4	87
23	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology, 2016, 90, 5899-5914.	3.4	62
24	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell, 2016, 166, 1471-1484.e18.	28.9	198
25	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nature Medicine, 2016, 22, 362-368.	30.7	163
26	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. Journal of Virology, 2016, 90, 1321-1332.	3.4	68
27	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. Journal of Virology, 2015, 89, 5895-5903.	3.4	92
28	Activation and lysis of human CD4 cells latently infected with HIV-1. Nature Communications, 2015, 6, 8447.	12.8	88
29	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Science Translational Medicine, 2014, 6, 243ra88.	12.4	222
30	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo. Journal of Virology, 2014, 88, 12669-12682.	3.4	248
31	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature, 2014, 514, 642-645.	27.8	308
32	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science, 2011, 333, 1593-1602.	12.6	788